Yersinia-specific antibodies in serum and synovial fluid in patients with yersinia triggered reactive arthritis

Outi Mäki-Ikola, Riitta Lahesmaa, Jürgen Heesemann, Riitta Merilahti-Palo, Riitta Saario, Auli Toivanen, Kaisa Granfors

Abstract

Objectives—To further evaluate the role of bacterial antigens in triggering inflammation in the joint in patients with reactive arthritis by studying local antibody synthesis in the joint.

Methods—Yersinia-specific antibodies in paired serum and synovial fluid samples from 29 patients with yersinia triggered reactive arthritis were studied using an enzyme linked immunosorbent assay (ELISA), an inhibition ELISA with six monoclonal antibodies against lipopolysaccharide or released proteins of yersinia and immunoblotting. Antibodies of IgM, IgG and IgA classes, as well as antibodies of IgA subclasses and those containing secretory component were measured against the lipopolysaccharide and the sodium dodecyl sulphate extract of whole Yersinia enterocolitica O:3 bacteria.

Results—It was shown that yersinia-specific antibodies, as well as antibodies against other microbial antigens (rubella, measles, Bordetella pertussis, tetanus toxoid and Candida albicans) in synovial fluid mirror those in serum by concentration, by specificity and by distribution in classes and subclasses.

Conclusion—These results do not suggest any strong local antibody production, but indicate that the majority of yersinia antibodies in the synovial fluid are derived from the circulation.


Patients and methods

PATIENTS AND SAMPLES

Paired serum and synovial fluid samples from 29 patients infected with Y enterocolitica O:3 were chosen from our large panel of samples collected from reactive arthritis patients for the present studies. Diagnosis of Yersinia infection was based in all patients on the typical clinical picture (diarrhoea, abdominal pain, vomiting and/or arthritis) and clearly increased levels of anti-yersinia antibodies detected by ELISA, in 16 cases, additionally, the pathogen was isolated from the stools. Age of the patients ranged from 13 to 72 years (mean 35), and the female to male ratio was 9:20. All patients developed ReA as a post infectious complication within three weeks after the onset of...
infection. Of the 27 patients tested, 23 were positive for the HLA B27 antigen. Serum and synovial fluid samples were collected simultaneously at 13 days to two months after the onset of infection; from one patient samples were taken at 8-5 months after the onset of infection. Synovial fluid aspirated from the knee was mixed with heparin (50 IU/ml), centrifuged at 200 g for 10 minutes and the supernatant was used for analysis. Both synovial fluid and serum samples were stored at −20°C and studied simultaneously.

Serum and synovial fluid samples from nine patients with ReA triggered by microbes other than yersiniae (5, salmonellae; 2, *Chlamydia trachomatis*; 1, *Y. pseudotuberculosis* and 1, unknown aetiology), from four patients with rheumatoid arthritis and from nine patients with swollen joints for other reasons (6 with swollen knee with unknown reason; 4 with chronic synovial inflammation with unknown reason, and 1 with colitis ulcerosa) served as controls.

**ANTIGENS**

As the source of RPs, plasmid-positive strain of *Y. enterocolitica* O:3 was grown and RPs prepared as previously described. The LPS was extracted from *Y. enterocolitica* O:3 using the phenol-water method. The SDS extract of whole *Y. enterocolitica* O:3 bacteria was also used as antigen.

**ELISA FOR ANTI-YERSINIA ANTIBODIES**

The ELISA procedures for IgM, IgG, IgA, IgA1 and IgA2 class yersinia antibodies and for yersinia antibodies containing secretory component (sIgA) have been reported earlier. Patient serum or synovial fluid samples at 1:250 dilution were allowed to react with SDS-extract of whole yersinia bacteria or LPS antigen attached to polystyrene microtiter plates. In IgM, IgG and IgA class assays alkaline-phosphatase-conjugated swine antibody to human IgM, IgG and IgA (Orion Diagnostica, Espoo, Finland) were used to detect bound antibodies. In IgA subclass analysis MoAbs against IgA1 or IgA2 (Becton Dickinson, Mountain View, California) were used to detect bound antibodies, after which rabbit anti-mouse immunoglobulin (Miles-Yeda, Kiryat Weizmann, Rehovot, Israel) absorbed with human IgG and swine alkaline phosphatase conjugated anti-rabbit IgG (Orion Diagnostica) were used. The sIgA antibodies were detected using rabbit immunoglobulins to human secretory component (DAKO Patts A/S, Glostrup, Denmark) and alkaline phosphatase conjugated swine anti-rabbit IgG (Orion Diagnostica). Fresh p-nitrophenyl phosphate in diethanolamine-MgCl2-buffer solution (Orion Diagnostica) was used as a substrate and the reaction was stopped with 1 M sodium hydroxide. The optical density was measured with a Titertek Multiscan Photometer (Labsystems, Helsinki, Finland) at a wavelength of 405 nm. Positive reference serum with high levels of yersinia antibodies was included on each plate. Antibody concentrations in the samples were expressed as relative units (enzyme immunoassay units; ELU): 1 U is 1/100 of the corresponding antibody concentration in the reference serum. Samples were tested as duplicates, and the results are expressed as the mean values.

**MONOCLONAL ANTIBODIES (MOABS)**

The MoAb 9-200 recognises the 46 kD/57 kD RP (YopM) and the MoAb PU-174 the 26 kD RP (YopE) of *Y. enterocolitica* O:3. The MoAbs 2C1, 6B6 and A6 react with the O-polysaccharide part of the LPS of *Y. enterocolitica* O:3. MoAb 2BS reacts with the outer core component of the *Y. enterocolitica* O:3 LPS. All these MoAbs have been described earlier.

**INHIBITION-ELISAS WITH MOABS**

The procedure was similar to that described earlier. Polystyrene microtiter plates were coated with RPs (Yops) or LPS of *Y. enterocolitica* O:3. A 75 μl portion of serum samples diluted 1:10 in RP-ELISA and 1:10 and 1:50 in LPS ELISA were incubated on the plates for 2 hours at 37°C. After washings, a 60 μl of the MoAb (at dilutions optimal for each MoAb; that is, 9–200 at 1:50, PU-174 at 1:2000, 2C1 at 1:2000, 6B6 at 1:15 000, 2B5 at 1:800 and A6 at 1:800 dilutions) was added to incubate overnight at room temperature. After washings, 60 μl of goat alkaline phosphatase-conjugated antisera (absorbed with human serum) specific for mouse IgG and IgM (TAGO, Burlingame, California) was added at a dilution of 1:4000 and incubated at 3 hours at 37°C. Quantitation by enzyme substrate was carried out as described earlier. Results were compared with values obtained by the MoAb alone (without serum sample) to calculate the inhibition percentage as described earlier.

**IMMUNOBLOTTING ANALYSIS OF IgG AND IgA CLASS ANTI-YERSINIA ANTIBODIES**

The SDS-polyacrylamide gel electrophoresis of whole *Y. enterocolitica* O:3 bacteria and immunoblotting were carried out as previously described.

**CONTROL ELISAS**

To compare serum and synovial fluid distribution of antibodies against other than the infecting microbe, the ELISAs for antibodies against *Bordetella pertussis*, tetanus toxoid, *Candida albicans*, rubella and measles were performed as described elsewhere.

**STATISTICS**

Wilcoxon test was used for comparison of antibody levels in serum and synovial fluid. Spearman’s correlation test was used to assess the degree of correlation between serum and synovial fluid antibody concentrations.
Table 1 Antibody concentrations (in EIU) against sodium dodecyl sulphate extract of whole Yersinia enterocolitica O:3 bacteria in paired serum and synovial fluid samples of patients with yersinia triggered reactive arthritis

<table>
<thead>
<tr>
<th>Serum</th>
<th>Synovial fluid</th>
<th>p*</th>
<th>Spearman’s correlation coefficient/P</th>
<th>Number of sample pairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM</td>
<td>122-8 (67-6)</td>
<td>0.0002</td>
<td>0.900-0000</td>
<td>26</td>
</tr>
<tr>
<td>IgG</td>
<td>85-9 (32-2)</td>
<td>0.03</td>
<td>0.740-0000</td>
<td>25</td>
</tr>
<tr>
<td>IgA</td>
<td>176-8 (99-4)</td>
<td>0.04</td>
<td>0.870-0000</td>
<td>25</td>
</tr>
<tr>
<td>IgA1</td>
<td>64-6 (33-6)</td>
<td>NS</td>
<td>0.650-0000</td>
<td>23</td>
</tr>
<tr>
<td>IgA2</td>
<td>42-4 (44-5)</td>
<td>NS</td>
<td>0.590-0022</td>
<td>23</td>
</tr>
<tr>
<td>sIgA</td>
<td>76-1 (59-8)</td>
<td>0.0001</td>
<td>0.900-0000</td>
<td>23</td>
</tr>
</tbody>
</table>

Mean (SD) values are given.

NS, not significant.

sIgA, IgA antibody containing secretory component.

*p Antibody concentrations between serum and synovial fluid samples are compared (Wilcoxon test).

†Between antibody concentrations in serum and synovial fluid samples.

Table 2 Inhibition of the binding of Yersinia enterocolitica O:3 lipopolysaccharide (LPS)-specific monoclonal antibodies (MoAbs) to Yersinia enterocolitica O:3 LPS by paired serum and synovial fluid samples from patients with yersinia triggered reactive arthritis

<table>
<thead>
<tr>
<th>MoAb Specificity</th>
<th>Sample dilution</th>
<th>Inhibition % in synovial fluid</th>
<th>p*</th>
<th>Spearman’s correlation coefficient/P</th>
<th>Number of sample pairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>2B5 Outer core of LPS</td>
<td>1:10</td>
<td>57-6 (29-1)/60-2 (28-7)</td>
<td>NS</td>
<td>0.770-0000</td>
<td>23</td>
</tr>
<tr>
<td>A6 O-poly saccharide of LPS</td>
<td>1:50</td>
<td>37-9 (28-4)/35-1 (24-9)</td>
<td>NS</td>
<td>0.950-0000</td>
<td>24</td>
</tr>
<tr>
<td>6B6 O-poly saccharide of LPS</td>
<td>1:50</td>
<td>31-9 (31-0)/29-1 (27-2)</td>
<td>NS</td>
<td>0.960-0000</td>
<td>24</td>
</tr>
<tr>
<td>2C1 O-poly saccharide of LPS</td>
<td>1:50</td>
<td>56-0 (35-0)/52-7 (35-1)</td>
<td>NS</td>
<td>0.930-0000</td>
<td>24</td>
</tr>
<tr>
<td>1:10</td>
<td>73-1 (50-7)/69-9 (37-4)</td>
<td>NS</td>
<td>0.810-0000</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>of LPS</td>
<td>1:50</td>
<td>58-6 (36-5)/54-0 (36-3)</td>
<td>NS</td>
<td>0.950-0000</td>
<td>24</td>
</tr>
</tbody>
</table>

Mean (SD) values are given.

*p Antibody concentrations between serum and synovial fluid samples are compared (Wilcoxon test).

†Between antibody concentrations in serum and synovial fluid samples.

Results

DIRECT ELISA FOR ANTI-yersinia antibodies

Paired samples of serum and synovial fluid from the patients with Y. enterocolitica O:3 infection were studied for the presence of anti-yersinia antibodies (table 1). In all assays the correlation between the antibody concentrations in serum and synovial fluid was good: Spearman’s correlation coefficient was from 0.59 to 0.90 (p from 0.0022 to 0.0001). The antibody levels against the SDS extract of whole bacteria as well as the LPS were significantly higher in the sera compared with the synovial fluid samples in IgM, IgG and IgA classes, as well as in sIgA (p from <0.04 to 0.0001); especially clearly the difference was seen in the IgM and sIgA classes. In the IgA1 and IgA2 subclass analysis there were no differences in the antibody levels between the sera and synovial fluid samples. No significant differences were found between the absorbance values in the SDS extract ELISA and the LPS ELISA indicating that the majority of the antibodies are directed against the LPS part of the bacteria.

INHIBITION ELISAS FOR YERSINIA antibodies

Paired samples of serum and synovial fluid from 17 patients with Y. enterocolitica O:3 infection were used to inhibit the binding of MoAbs to 26 kD and 46 kD RPs. None of the serum samples and four of the synovial fluid samples are able to inhibit the binding of MoAb PU-174 to 26 kD RP significantly more than sera taken from healthy controls [inhibition-% > mean + 2 SD in controls].

The corresponding figures were eight for serum samples and 12 for synovial fluid samples when inhibition of MoAb 29–200 to 46 kD RP was studied. When the mean (SD) inhibition-% of all the serum or synovial fluid samples was studied, the serum samples were able to inhibit the binding of 26 kD RP-specific MoAb 38–4% (34–8), with 20–3% (29–9) inhibition with synovial fluid samples. Thus there were no statistically significant differences in the concentrations of antibodies to the MoAb PU-174-defined epitope of 26 kD RP between the sera and synovial fluids. Accordingly, there were no differences in the ability to inhibit the binding of 46 kD RP-specific MoAb to 46 kD RP between serum [mean (SD) 58–8% (28–7)] and synovial fluid [65–9% (31–8)] samples.

Similarly, when paired serum and synovial fluid samples were studied, there were no significant differences in the antibody concentrations against the MoAb 2B5-, A6-, 6B6- and 2C1-defined epitopes of Y. enterocolitica O:3 LPS between sera and synovial fluids (table 2). There was a good correlation between the antibody concentrations in sera and synovial fluids in all assays; Spearman’s correlation coefficient was from 0.70 to 0.96 (p from 0.0002 to 0.0000).

IMMUNOBLOTTING

To study whether we can identify qualitative differences in the antibody reactivity to various yersinia antigens, paired serum and synovial fluid samples were analysed by immunoblotting with whole Y. enterocolitica O:3 bacteria as antigen in the nitrocellulose sheet. Based on this extensive analysis, identical panel of Y. enterocolitica antigens was recognised by IgG and IgA of the serum and synovial fluid samples (figure).

CONTROL ELISAS

The antibody level in serum samples was higher than in synovial fluid samples when IgG class antibodies against tetanus toxoid, measles and rubella were studied. Also the level of IgM, IgG and IgA class antibodies against Candida albicans was higher in serum samples compared with synovial fluid samples (table 3).

CONTROL SAMPLES

Paired serum and synovial fluid samples from 22 control patients with other rheumatic diseases than yersinia triggered ReA were studied for the presence of yersinia-specific antibodies, as well as antibodies against the above mentioned control microbes. The yersinia antibody levels were always low. There were no differences in the antibody levels between sera and synovial fluids in IgM, IgG, IgA and sIgA class ELISAs using LPS as antigen, or in IgG and sIgA class using SDS extract of whole bacteria as antigen. In IgM and IgA class with SDS extract antigen the antibody concentration was higher in serum
**Table 3** Antibody concentrations against control microbes in paired serum and synovial fluid samples of patients with yersinia triggered reactive arthritis

<table>
<thead>
<tr>
<th></th>
<th>Serum</th>
<th>Synovial fluid</th>
<th>P*</th>
<th>Number of sample pairs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tetanus toxoid, IgG</strong></td>
<td>10.1 (9.2)</td>
<td>7.3 (8.0)</td>
<td>&lt;0.01</td>
<td>19</td>
</tr>
<tr>
<td><strong>Measles, IgG</strong></td>
<td>4.2 (5.4)</td>
<td>3.7 (3.3)</td>
<td>&lt;0.05</td>
<td>25</td>
</tr>
<tr>
<td><strong>Rubella, IgG</strong></td>
<td>4.0 (2.7)</td>
<td>3.9 (3.2)</td>
<td>&lt;0.01</td>
<td>25</td>
</tr>
<tr>
<td><strong>Candida albicans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgM</td>
<td>0.559 (0.226)</td>
<td>0.370 (0.205)</td>
<td>&lt;0.0005</td>
<td>22</td>
</tr>
<tr>
<td>IgG</td>
<td>1.186 (0.416)</td>
<td>1.047 (0.444)</td>
<td>&lt;0.01</td>
<td>22</td>
</tr>
<tr>
<td>IgA</td>
<td>0.538 (0.241)</td>
<td>0.421 (0.249)</td>
<td>&lt;0.0005</td>
<td>22</td>
</tr>
</tbody>
</table>

Mean (SD) values are given.

*ELISA, enzyme immunoassay unit.
†Absorbance value.
‡Antibody concentrations between serum and synovial fluid samples are compared (Wilcoxon test).

**Discussion**

In the present study we demonstrate that in patients with yersinia triggered ReA yersinia-specific antibodies in the synovial fluid mirror those in the serum as judged by concentration, by specificity or by distribution in antibody classes or subclasses (p always <0.003 for correlation). When there was a statistically significant difference in the antibody concentrations between serum and synovial fluid samples, the antibody level was always higher in serum compared to synovial fluid. These results do not speak for any strong local antibody production, but indicate that the majority of yersinia antibodies in the synovial fluid are derived from the circulation. The results from assays with microbes unrelated to yersinia infections as antigens support this concept. Accordingly, no significant differences were found in the antibody levels against *Chlamydia trachomatis*, *Yersinia enterocolitica* or *Borrelia burgdorferi* between serum and synovial fluid samples from patients with undifferentiated oligoarthritis. Further, the difference in antibody concentrations between serum and synovial fluid samples was biggest in IgM and sIgA (the largest immunoglobulin molecules in size) assays, which is in line with the above suggestion of filtration of the antibodies from circulation into the joint.

Controversially, we have recently found evidence for intra-articular antibody production of IgA2 subclass against salmonella LPS in patients with salmonella triggered ReA. Most of the circulating IgA belongs to the subclass IgA1, whereas in locations close to mucosal surfaces, especially the distal gut where salmonella invades the mucosa, the number of IgA2 producing cells is increased. Thus antibodies of IgA2 subclass in synovial fluid were thought to indicate mucosal origin. It was speculated that the high level of IgA2 class salmonella specific antibodies in the joint was a result of selective migration of IgA2-secreting lymphocytes from the distal gut mucosa to synovium, where the existing salmonella LPS may have stimulated local IgA2 class antibody production. However, yersinia penetrates the mucosa in the proximal part of the gut, where no increased number of IgA2 producing cells are seen. Thus if the intra-articular antibody production suggested in salmonella triggered ReA is subclass specific, the difference in the location of invasion between salmonella and yersinia may explain why IgA2 class anti-yersinia antibodies may not have been produced locally in the joints in patients with yersinia triggered ReA. It is, however, important to note that higher antibody concentrations are generally detected in the serum, as shown here and also, for example, in patients with rheumatoid arthritis. Therefore even if the concentration of antibodies in synovial fluid was lower than that observed in serum, the synovial fluid may have contained locally produced antibodies. Further, it is also possible that some of the synovial fluid antibodies are lost in the assays due to the formation of immune complexes and subsequent trapping in the cartilage.
Yersinia-specific antibodies in serum and synovial fluid in patients with yersinia triggered reactive arthritis

Likewise, it is possible that the finding of similar levels in serum and synovial fluid yersinia-specific IgA1 and IgA2 subclasses, as well as of IgA and IgG classes would be of some importance, since the differences in antibody levels in serum and synovial fluid in other immunoglobulin classes and in controls against other organisms are much more striking than in these mentioned tests.

The role of RPs in the pathogenesis of ReA has not been well studied yet. There are some indications for RPs to play some role in the pathogenesis of ReA: 1) patients with yersinia-triggered ReA have more often antibodies against the 36 kD RP and higher concentrations of antibodies against the 26 kD RP in the beginning of the disease than the patients who recover from the infection without arthritis; 11 12 2) total amount of IgA class antibodies against RPs is significantly higher in arthritic patients in the beginning of the disease; 3) yersinia bacilli was demonstrated in the intestinal biopsy specimens of patients with yersinia-triggered ReA by immunofluorescence using monospecific rabbit antisera to 46 kD RP21 and 4) strong T-cell reactivity to RPs was detected in synovial fluid samples taken from patients with reactive arthritis.22 23 In the present study we could find no evidence for intra-articular antibody production against the two MoAb-defined epitopes of 26 kD and 46 kD RPs. The intrasynovial antibodies also against RPs may have therefore filtrated to the joint from the circulation rather than been produced locally. Thus the involvement of RPs in the pathogenesis of ReA remains open to speculation.

In ReA, microbial antigens enter the body via mucosal surfaces. Subsequently, microbial LPS is transported to the joints.1 3 5 Microbial antibodies are produced and may filtrate into the synovium from circulation, or as in case of salmonella triggered ReA, they may be produced locally in the joints.6 Antibodies may also be transported to the joint as part of immune complexes, as immune complexes consisting of yersinia antigen and specific antibody are found in the circulation as well as in synovial fluid in yersinia triggered ReA.27 The specific antibodies together with microbial antigens in the joint may participate in inflammation and tissue injury through complement activation. LPS may play an important role in these events, as a major part of yersinia-specific antibodies in serum and synovial fluid in patients with ReA were directed against LPS. Our previous studies also suggest a crucial role for LPS in the pathogenesis of ReA.1 4 8 10 28

We thank Professor David T Y Yu for 2C1 and 6B6 monoclonal antibodies, Dr Rauli Leino for some of the patient samples and records, Rajia Vainionpää for analysing the viral antibodies and Mrs Soli Mänttäri and Mrs Maija Salonen for technical assistance. Our study was supported by the grants from the Rheumatism Research Foundation, the Turku University Fund, the University of Jyväskylä Foundation, the Sigrid Juselius Foundation and the Finnish Academy, and by contract with the Finnish Life and Pension Insurance Companies.

Yersinia-specific antibodies in serum and synovial fluid in patients with Yersinia triggered reactive arthritis.

O Mäki-Ikola, R Lahesmaa, J Heesemann, R Merilahti-Palo, R Saario, A Toivanen and K Granfors

doi: 10.1136/ard.53.8.535

Updated information and services can be found at:
http://ard.bmj.com/content/53/8/535

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/